AbCellera-discovered bamlanivimab combo shows promise in late-stage COVID-19 trial

 

• AbCellera (ABCL +6.0%) announces that bamlanivimab (LY-CoV555) 700 mg, a human antibody discovered by AbCellera and developed with Eli Lilly (NYSE:LLY), and etesevimab 1400 mg (LY-CoV16) together reduced COVID-19-related hospitalizations and deaths by 87% in high-risk patients recently diagnosed with COVID-19.
• The results from this new randomized, double-blind, placebo-controlled Phase 3 BLAZE-1 study provide additional efficacy and safety data that support the use of the dose recently granted both EUA by the U.S. FDA, and a positive scientific opinion by the EMA CHMP.
• 87% reduction in COVID-19-related hospitalizations and deaths versus placebo (p<0.0001).
• No COVID-19-related deaths in the treatment group. All deaths occurred in patients treated with the placebo.
• Bamlanivimab alone and together with etesevimab are authorized under special/emergency pathways, in the context of the pandemic, in the U.S. and the European Union, the company said.

https://newsfilter.io/search